Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report

다국어 초록 (Multilingual Abstract)

This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N ‐(3‐Fluoropropyl)‐2β‐carbon ethoxy‐3β‐(4‐iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.

참고문헌 (Reference)

1 Frank S, "Treatment of Huntington’s disease" 11 : 153-160, 2014

2 Hamilton M, "The assessment of anxiety states by rating" 32 : 50-55, 1959

3 Edwards MJ, "Neurobiology of functional(psychogenic)movement disorders" 26 : 442-447, 2013

4 Billnitzer A, "Current management of tics and tourette syndrome : behavioral, pharmacologic, and surgical treatments" 17 : 1681-1693, 2020

5 Cunningham MW, "Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond" 216 : 90-100, 2016

6 Tuplin EW, "Aripiprazole, a drug that displays partial agonism and functional selectivity" 15 : 1192-1207, 2017

7 Di Sciascio G, "Aripiprazole : from pharmacological profile to clinical use" 11 : 2635-2647, 2015

8 Fobian AD, "A review of functional neurological symptom disorder etiology and the integrated etiological summary model" 44 : 8-18, 2019

9 Hamilton M, "A rating scale for depression" 23 : 56-62, 1960

10 Yoo HK, "A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder" 74 : e772-e780, 2013